Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
T-cellymfoom na CAR T-celtherapie zeldzaam; genetische modificatie van cellen niet altijd de oorzaak
nov 2024 | Lymfoom